Shares of Innocoll Holdings plc jumped 47.8 percent Wednesday on word that two phase III trials testing Xaracoll, its long-acting bupivacaine implant, solidly hit their primary endpoints in a postoperative pain study, findings that bode well for the company’s overall collagen-matrix platform technology, even if analysts await greater clarity to gauge the product’s potential in the non-opioid analgesic market.